A clinical-stage biotechnology company developing gene therapies using adeno-associated virus (AAV) vectors. Its proprietary NAV Technology Platform is used both in internal drug programs targeting rare genetic diseases and through licensing agreements with pharmaceutical partners. Investors track t...
1 member of Congress has disclosed 1 trade in REGENXBIO Inc. (RGNX), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2024-12-20 | Anna Paulina Luna | sell | $15K – $50K |